Sotalol – class IIIa

Sotalol – class IIIa Sotalol is a class IIIa antiarrhythmic agent as per the Modernized Classification of Cardiac Antiarrhythmic Drugs [1]. The class effect is voltage dependent K+ channel blocker. Specifically, it is a HERG channel –mediated rapid K+ current (IKr) blocker. It has additional action on beta 1 and beta 2 receptors. Sotalol increases refractory period and decreases tendency for reentry. The drug is useful in ventricular tachycardia without structural heart disease and in those with a remote myocardial infarction. It is also useful in atrial fibrillation with conduction through accessory pathway in WPW syndrome. It is also useful in other supraventricular arrhythmias. Sotalol is useful in prevention of ventricular fibrillation and premature ventricular contraction. The drug has a half life of 12 hours and a 12th hourly dosage is advised. It can cause QTc prolongation and torsades de pointes [3]. References Ming Lei, Lin Wu, Derek A Terrar, Christopher L-H Huang. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018 Oct 23;138(17):1879-1896. Sana M Al-Khatib, William G Stevenson, Michael J Ackerman, William J Bryant, David J Callans, Anne B Curtis, Barbara J Deal, Timm Dickfeld, Michael E Field, Gregg C Fonarow, Anne M Gillis, Christopher B Granger, Stephen C Hammill, Mark A Hlatky, José A Joglar, G Neal Kay, Daniel D Matlock, Robert J Myerburg, Richard L Page. 2017 AHA/ACC/HRS Guideline for Management of Patients With V...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: ECG / Electrophysiology Source Type: blogs